We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Culture Technique Generates Large Numbers of Functional Human Muscle Cells

By LabMedica International staff writers
Posted on 30 Mar 2014
A novel technique that uses free-floating spherical culture (EZ spheres) in a defined, serum-free culture medium generated large numbers of functional muscle cells from human embryonic stem (hES) and induced pluripotent stem (iPS) cells.

Investigators at the University of Wisconsin (Madison, USA) used the EZ sphere procedure to transform hES and iPS cells into myogenic progenitors by growing the cells in serum-free medium that was supplemented with high concentrations of fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). More...


They reported in the March 21, 2014, online edition of the journal Stem Cells Translational Medicine that under these culture conditions myogenic progenitors were detectable in the spheres after six weeks of culture and multinucleated myotubes following sphere dissociation and two weeks of terminal differentiation. A high concentration of FGF-2 played a critical role for myogenic differentiation and was necessary for generating myogenic progenitors from pluripotent cells cultured as EZ spheres.

Approximate 40% to 60% of the cells grown using this process matured into either muscle cells or muscle progenitors, a high proportion compared to traditional nongenetic techniques of generating muscle cells from human ES and iPS cells. Furthermore, EZ sphere culture was capable of producing myogenic progenitors from human iPS cells generated from both healthy donors and patients with neuromuscular disorders (including Becker’s muscular dystrophy, spinal muscular atrophy, and familial amyotrophic lateral sclerosis).

"Researchers have been looking for an easy way to efficiently differentiate stem cells into muscle cells that would be allowable in the clinic," said senior author Dr. Masatoshi Suzuki, assistant professor of comparative biosciences at the University of Wisconsin. "The novelty of this technique is that it generates a larger number of muscle stem cells without using genetic modification, which is required by existing methods for making muscle cells. Our protocol can work in multiple ways and so we hope to provide a resource for people who are exploring specific neuromuscular diseases in the laboratory."

Related Links:

University of Wisconsin



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Immunofluorescence Analyzer
IFA System
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.